Onfekafusp alfa

DB16269InvestigationalProtein Based Therapies

Onfekafusp alfa is under investigation in clinical trial NCT02938299 (Neoadjuvant L19IL2/L19TNF- Pivotal Study).

Mechanism
Curator reviewed
Also known as
Daromun component l19tnf · Fibromun · Immunoglobulin, anti-(human fibronectin ed-b domain) (synthetic human clone l19 scfv fragment) fusion protein with human tumor necrosis factor .alpha., trimer
Code names
L19-TNF

Resolves to

Compound
UNII6HXC0O6JMVCAS1957239-88-1
Clinical / RWD
ATCL01XY04
Targets
P02751FN1

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
17Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1ATC codeIncluding every combination product, plus 2 drug categories
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Onfekafusp alfa, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In